Inbrija

Levodopa, the active ingredient in Inbrija, is a dopamine precursor presented as an inhalation powder for inhalation use. It is used to treat OFF episodes in Parkinson's disease as an adjunct therapy for patients already receiving oral levodopa.\n\nGNH India supplies Inbrija as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inbrija is indicated for adjunct therapy in Parkinson's disease, targeting motor fluctuations associated with dopaminergic deficiency.\n\n- OFF episodes in Parkinson's disease: rapid relief of motor symptoms during periods of reduced oral levodopa effect.\n- Adjunct to oral levodopa therapy: enhances overall dopaminergic coverage and reduces OFF time.\n- Motor fluctuations in Parkinson's disease: decreases the duration and severity of OFF periods when combined with standard treatment.

Inbrija may cause a range of adverse reactions.\n\nCommon Side Effects:\n- Cough or throat irritation\n- Nausea\n- Dizziness\n- Headache\n- Dry mouth\n- Upper respiratory discomfort\n\nSerious or Rare Side Effects:\n- Dyskinesia (involuntary movements)\n- Orthostatic hypotension\n- Hallucinations or psychosis\n- Pulmonary edema\n- Severe allergic reactions (anaphylaxis)\n- Respiratory compromise in patients with underlying lung disease

Prior to initiating Inbrija, clinicians should consider several safety measures.\n\n- Cardiovascular assessment: monitor for orthostatic hypotension and blood pressure changes.\n- Concomitant MAO‑B inhibitors: avoid use together due to risk of hypertensive reactions.\n- Respiratory conditions: use with caution in patients with asthma, COPD, or other chronic lung diseases.\n- Dyskinesia monitoring: adjust oral levodopa dose if excessive involuntary movements develop.\n- Store at ambient temperature: keep in the original container, protect from moisture and heat.

Inbrija can interact with several medication classes.\n\nMajor Interactions (Avoid):\n- Non‑selective MAO inhibitors: risk of hypertensive crisis.\n- MAO‑B inhibitors (e.g., selegiline, rasagiline): may increase levodopa plasma levels.\n- Pyridoxine (vitamin B6) at high doses: can reduce levodopa efficacy.\n\nModerate Interactions (Monitor Closely):\n- Anticholinergic agents: may enhance anticholinergic side effects.\n- Dopamine antagonists (e.g., typical antipsychotics): may diminish therapeutic response.